176 APPENDICES How to monitor safety and efficacy of biologic treatment in rare, therapy refractory immune-mediated inflammatory diseases?: Making the right clinical dicisions for rare diseases with the right tools Musters A, Tas SW Rheumatology. 2018 Apr 1;57(4):591-593. PMID: 28339729 Rare rheumatic diseases of immunologic dysregulation - Chapter 6: Castleman’s Disease Musters A, Tas SW Springer. 2018 Oct 29:121-138. ISBN 978-3-319-99138-2. Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis Quistrebert J, Hässler S, Bachelet D, Mbogning C, Musters A, Tak PP, Wijbrandts CA, Herenius M, Bergstra SA, Akdemir G, Johannesson M, Combe B, Fautrel B, Chollet-Martin S, Gleizes A, Donnellan N, Deisenhammer F, Davidson J, Hincelin-Mery A, Dönnes P, Fogdell-Hahn A, De Vries N, Huizinga T, Abugessaisa I, Saevarsdottir S, Hacein-Bey-Abina S, Pallardy M, Broët P, Mariette X, on behalf of the ABIRISK Consortium Seminars in Arthritis and Rheumatism. 2019 Jun;48(6):967-975. PMID: 30420245 Room for improvement in clinical trials for rare diseases Musters A, Tas SW Nature Reviews Rheumatology. 2020 Mar;16(3):131-132. PMID: 31996788 Understanding repertoire sequencing data through a multiscale computational model of the germinal center García-Valiente R, Merino Tejero E, Stratigopoulou M, Balashova D, Jongejan A, Lashgari D, Pélissier A, Caniels TG, Claireaux MAF, Musters A, van Gils MJ, Rodríguez Martínez M, de Vries N, Meyer-Hermann M, Guikema JEJ, Hoefsloot H, van Kampen AHC NPJ Systems Biology and Applications. 2023 Mar 16;9(1):8. PMID: 36927990 Systematic evaluation of B-cell clonal family inference approaches Balashova D, van Schaik BDC, Stratigopoulou M, Guikema JEJ, Caniels TG, Claireaux M, van Gils MJ, Musters A, Anang DC, de Vries N, Greiff V, van Kampen AHC Submitted for publication
RkJQdWJsaXNoZXIy MTk4NDMw